retatrutide phase 2 nejm 2023 percent weight loss 48 weeks (not yet approved in US but people using anyway) promises even potentially greater amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 24.2%. That's the mean body

In general, it is much safer to take the name-brand versus compounded versions. 3

Histologic evidence from liver biopsiesthe definitive method for diagnosing and staging NASHhas been more limited but encouraging

Although the general opposing behavioral outcomes related to food-motivated behavior for the GLP-1 and ghrelin systems are similar across sexes, the specific underlying mechanisms mediating neural sites of action can diverge

In summary, different GLP-1RAs improve skeletal muscle atrophy through multiple molecular mechanisms, involving multiple pathways such as insulin resistance regulation, inflammation suppression, and mitochondrial function improvement (see Table 1), providing a theoretical basis for the clinical treatment of sarcopenia with GLP-1RAs

While I do not crave sweets any longer for those few days pre-period that I used to, I do not find any less motivation, ambition, joy, or energy